Company / Interest Expense
INOVIO PHARMACEUTICALS, INC. Interest Expense History
FY2019-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$1.9M
FY2023
5-year range
$1.9M / $8.7M
FY2019-FY2023
Trend
-77.7%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $8M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2023.
Improved from $8M to $2M over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, interest expense decreased 77.7% year-over-year.
- Peak interest expense was recorded in FY2022.
- Lowest interest expense in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $1.9M | -77.7% |
| FY2022 | $8.7M | +9.5% |
| FY2021 | $7.9M | - |
| FY2020 | $0 | -100.0% |
| FY2019 | $25.9K | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026